Daniel Murphy

Daniel Murphy

Auto-generated profile, based on publicly available information

Daniel Murphy

St George’s University Hospitals NHS Foundation Trust, London, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2021 in European Journal of Orthopaedic Surgery & Traumatology
Verified
Journal Article
Closed access
PDF file
DMDaniel Murphy
Daniel Murphy
MRMohsen Raza
Mohsen Raza
FMFergal Monsell
Fergal Monsell
YGYael Gelfer
Yael Gelfer

1 May 2021 in EFORT Open Reviews
Verified
Journal Article
Open access
DMDaniel Murphy
Daniel Murphy
MRMohsen Raza
Mohsen Raza
HKHiba Khan
Hiba Khan
DEDeborah M. Eastwood
Deborah M. Eastwood
YGYael Gelfer
Yael Gelfer
Equinus contracture is the most common deformity at clubfoot relapse and causes pain and functional limitation. It presents a challenge to the orthopaedic surgeon throughout childhood. A systematic review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies included were: (i) original articles, (ii) investigating management of relapsed idiopathic clubfoot, (iii) with at least a partial study population of primarily equinus deformity, and (iv) a paediatric study population of independent walking age. Nine studies were included with a total of 163 patients (207 feet). Studies presented five management paradigms: gastrocnemius-soleus complex release, extensive posterior soft tissue and joint release, anterior distal tibial hemi-epiphysiodesis, distal tibial osteotomy, and circular frame distraction. All approaches reported success in at least one of our selected outcome domains: plantigrade status, range of motion, clinical outcome scores, functional status, radiographic outcomes, patient-reported outcomes, and complications. Younger children tend to be managed with soft tissue release while older children tend to require more extensive bone/joint procedures. Relapse in surgically treated feet is harder to treat. Comparison across treatment approaches is limited by the small size and low evidence level of the literature, as well as a lack of consistent outcome reporting. It is therefore not possible to recommend any one treatment option in any age group. This review highlights the need for a validated core outcome set to enable high-quality research into the management of equinus deformity. Cite this article: EFORT Open Rev 2021;6:354-363. DOI: 10.1302/2058-5241.6.200110

31 March 2023
Verified
Book Chapter
Closed access
PDF file
DMDaniel Murphy
Daniel Murphy
VJVivekanand Jha
Vivekanand Jha
DBDebasish Banerjee
Debasish Banerjee

12 August 2023 in The American Journal of Cardiology
Verified
Journal Article
Closed access
DMDaniel Murphy
Daniel Murphy
SFSami Firoozi
Sami Firoozi
CHCharles A Herzog
Charles A Herzog
DBDebasish Banerjee
Debasish Banerjee

14 October 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
DBDebasish Banerjee
Debasish Banerjee
MAMahrukh Ali
Mahrukh Ali
ETElla Tumelty
Ella Tumelty
DMDaniel Murphy
Daniel Murphy
HWHilary Warrens
Hilary Warrens
LALisa Anderson
Lisa Anderson
Renin-angiotensin-aldosterone inhibitors (RAASi) improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF), but their use is often limited by hyperkalaemia in chronic kidney disease (CKD) patients. This double-blind, placebo-controlled, randomised trial evaluated whether sodium zirconium cyclosilicate (SZC) enables RAASi up-titration in HFrEF patients with CKD stages 3–5 and serum potassium of 5.0–5.5 mmol/L over 14 weeks. The primary binary outcome was defined as achieving the target dose of RAAS inhibition therapy without reaching hyperkalaemia (serum potassium ≥5.6 mmol/L) over 14 weeks or otherwise. Participants ( n = 112) were randomised 1:1 to receive sodium zirconium cyclosilicate (SZC) or placebo. The per-protocol (PP) analyses included 43 out of 53 (81%) in the SZC arm and 53 out of 59 participants (90%) in the placebo arm; the intention-to-treat (ITT) analyses included all 112. At the end of the trial, 24 of 43 participants (56%) in the SZC group achieved the target RAASi dose without developing hyperkalaemia compared with 15 of 53 patients (28%) in the placebo group (PP analysis, p = 0.006, ITT analysis, p = 0.007,). Participants in the SZC group were 3 times more likely to reach the target dose without reaching potassium 5.6 mmol/L (OR = 3.16; 95% CI 1.35–7.39; p = 0.008) than in the placebo group (ITT analysis). No significant differences in adverse events between the two groups were observed. SZC appears to safely support rapid RAASi optimisation in HFrEF patients with CKD. This trial was funded by AstraZeneca via Externally Sponsored Scientific Research grant ESR-19-20174. Trial Registration: Clinicaltrials.gov NCT05004363 and EudraCT number 2020-002946-18.